Adverse events165

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 165

Type	Event	Organ system	Group	Affected	At risk	Events
other	Alanine aminotransferase increased	Investigations	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	6
other	Alanine aminotransferase increased	Investigations	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	0	4
other	Alanine aminotransferase increased	Investigations	PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2	0	29
other	Aspartate aminotransferase increased	Investigations	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	6
other	Aspartate aminotransferase increased	Investigations	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	0	4	0
other	Aspartate aminotransferase increased	Investigations	PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2	0	29
other	Diarrhea	Gastrointestinal disorders	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	2	6
other	Diarrhea	Gastrointestinal disorders	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	0	4
other	Diarrhea	Gastrointestinal disorders	PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2	1	29
other	Fatigue	General disorders	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	6
other	Fatigue	General disorders	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	4
other	Fatigue	General disorders	PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2	2	29
other	Hypertension	Vascular disorders	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	6
other	Hypertension	Vascular disorders	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	0	4
other	Hypertension	Vascular disorders	PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2	2	29
other	Hyponatremia	Metabolism and nutrition disorders	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	6
other	Hyponatremia	Metabolism and nutrition disorders	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	4
other	Hyponatremia	Metabolism and nutrition disorders	PhaseII Dasatinib 100mg/Trastuzumab 2mg/kg/Paclitaxel 80mg/m2	2	29
other	Tumor pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Dasatinib 100mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	1	6
other	Tumor pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Dasatinib 140mg + Trastuzumab 2mg/kg + Paclitaxel 80mg/m2	0	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01306942/events

API reference For AI assistants

Adverse events165

Sources 3

Read this list from software.